Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03861741
Other study ID # 0676
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 1, 2019
Est. completion date May 20, 2022

Study information

Verified date April 2021
Source University of Leicester
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary hypothesis is that a tailored programme of genetic and imaging screening of first- and second-degree relatives of patients affected by non-syndromic forms of thoracic aortic diseases will identify individuals at risk of death from these conditions. These individuals would constitute specific population of patients, requiring dedicated imaging surveillance and/or earlier prophylactic aortic surgery.


Description:

Diseases involving the thoracic aorta (the major artery in the body) are a major health problem affecting an increasing number of people worldwide. In particular, a group of these conditions termed Non-Syndromic Aortic Diseases (NS-TAD), can develop without any obvious symptoms or external features which prevents early identification. Unfortunately, if not treated, the aorta may enlarge and lead to dissection, a life-threatening medical emergency. For this reason, the investigators believe it might be helpful to investigate relatives of patients undergoing surgery for thoracic aortic disease to understand if there are tests that could help identify and treat this condition at the right time. Therefore the investigators propose to conduct a feasibility study to identify the practical issues and challenges that would need to be overcome in order to perform a successful tailored genetic (by collecting a small blood sample) and imaging (with exams such as echocardiography and MRI) screening in such population of individuals. Moreover, all participants will receive two questionnaires to ask their opinion about the study and to measure their levels of anxiety and depression, to judge whether and how this study has affected their emotional status. The study will be carried out at the Department of Cardiovascular Sciences Glenfield Hospital, University Hospitals of Leicester NHS Trust.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 70
Est. completion date May 20, 2022
Est. primary completion date May 20, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: 1. NS-TAD probands operated on (n=16). 2. FDR and SDR, aged 16 and above: 1. At least two relatives willing to participate in the screening programme. 2. Relatives able to understand English. Exclusion Criteria: 1. Probands with syndromic aortopathies, including Marfan Syndrome, Loeys-Dietz Syndrome, Ehlers-Danlos Syndrome, Shprintzen-Goldberg syndrome, aneurysm-osteoarthritis syndrome, arterial tortuosity syndrome, and cutis laxa syndrome. 2. Probands with aortic lesions associated with trauma and infections. 3. Probands/relatives unable to give informed consent

Study Design


Intervention

Genetic:
WES
A peripheral venous blood sample will be processed internally, and externally subjected to WES. Only genetic material from relatives of probands in which a mutation has been identified will be sequenced.
Diagnostic Test:
MRI
A MRI of the thoracic aorta will be performed in all relatives able to attend the Glenfield Hospital and who have no contra-indications to this imaging modality; pulse-wave velocity will be recorded.
TTE
TTE screening will be performed by a trained physiologist. Aortic diameter will be measured from the parasternal long-axis view at the sinuses of Valsalva and at the widest level of the ascending aorta. All measurements will be made in end-diastole.
Other:
Questionnaire
Acceptability questionnaires will be submitted to assess a baseline score of depression/anxiety that will be compared with a follow up value at three months

Locations

Country Name City State
United Kingdom Department of Cardiovascular Sciences Leicester Leicestershire

Sponsors (1)

Lead Sponsor Collaborator
University of Leicester

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Mariscalco G, Debiec R, Elefteriades JA, Samani NJ, Murphy GJ. Systematic Review of Studies That Have Evaluated Screening Tests in Relatives of Patients Affected by Nonsyndromic Thoracic Aortic Disease. J Am Heart Assoc. 2018 Aug 7;7(15):e009302. doi: 10.1161/JAHA.118.009302. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of genetic diagnosis Frequency of first and second degree relatives with newly identified genetic loci associated with NS-TADs. Through study completion, an average of 1 year
Primary Rate of diagnosis through imaging modalities Frequency of newly diagnosed TAD through imaging modalities in first- and second-degree relatives of probands affected by NS-TADs. At the end of recruitment stage, an average of 6 months
Secondary Genetic variants Genetic variants associated with NS-TADs, identified from a panel of 55 loci, and rate of identification of each mutation. Through study completion, an average of 1 year
Secondary Family rate of genetic carriers Rate of genetic carriers in each affected family. Through study completion, an average of 1 year
Secondary Penetrance Genetic penetrance of the NS-TADs (proportion of individuals carrying a particular variant of a gene that are also affected by NS-TAD). Through study completion, an average of 1 year
Secondary Mode of inheritance Pattern of inheritance of the NS-TADs. Through study completion, an average of 1 year
Secondary Male: female preponderance Male: female preponderance of NS-TADs. Through study completion, an average of 1 year
Secondary Aortic Compliance Measured as an MRI feature of affected and unaffected thoracic aortas. Imaging tests completion, an average of 6 months.
Secondary Aortic Distensibility Measured as an MRI feature of affected and unaffected thoracic aortas. Imaging tests completion, an average of 6 months.
Secondary Rates of concomitant external and cardiovascular characteristics Rates of concomitant cardiovascular diseases (e.g. patent ductus arteriosus, cerebrovascular aneurysm) and external physical features (e.g. pectus excavates, livedo reticularis). Baseline clinical assessment
Secondary Response rate Response rates (recruitment) among the probands and their relatives. Baseline clinical assessment
Secondary Acceptability questionnaires Semi-quantitative evaluation of the participant experience awareness and acceptability of the screening and consent process, obtained by questionnaires administered to the patients and relatives.
Scales will be composed by 10 items, each can be rated with a score from 1 to 5. No threshold will be preset. Descriptive statistics will be used to present the results.
Baseline and 3 months follow up
Secondary Depression evaluation Semi-quantitative evaluation of the impact of the screening process on depression in probands and their relatives (baseline and 3 months), based on Patient Health Questionnaire (PHQ-9) score. Score range goes from 0 to 27, proposed cut-off for active treatment is 15. Baseline and 3 months follow up
Secondary Anxiety evaluation Semi-quantitative evaluation of the impact of the screening process on anxiety in probands and their relatives (baseline and 3 months), based on Generalized Anxiety Disorder (GAD-7) score. Score range goes from 0 to 21, proposed cut-off for further assessment is 10. Baseline and 3 months follow up
Secondary Health-related Quality of Life evaluation Semi-quantitative evaluation of the impact of the screening process on health-related quality of life in probands and their relatives (baseline and 3 months), based on Short Form (36) Health Survey (SF-36) score. Said questionnaire is made up of eight scales, which are the weighted sums of the items for each section; a score of zero corresponds to maximum disability while 100 correlates to no disability. Baseline and 3 months follow up
Secondary Resource use of genetic screening Resource uses in terms of unitary costs of the genetic screening process. 3 months follow up
Secondary Resource use of imaging screening Resource uses in terms of unitary costs of the imaging screening process. 3 months follow up
Secondary Resource use (hospital visits) Number of participants reaching the research centre. 3 months follow up
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03548779 - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 N/A
Completed NCT03292302 - Phase 1 Study of ELX-02 in Healthy Adults Phase 1
Withdrawn NCT03658382 - Virtual Visits for Results Disclosure N/A
Recruiting NCT02266615 - Biobank Clinical Genetics Maastricht (KG01)
Recruiting NCT02450851 - Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network
Recruiting NCT05472714 - Educational Video for Genetic Testing N/A
Recruiting NCT04285814 - Technology Development for Noninvasive Prenatal Genetic Diagnosis Using Whole Fetal Cells From Maternal Peripheral Blood
Completed NCT05443113 - Young Pectus Excavatum Patients and Genetic Defects
Completed NCT05655741 - Modified Delphi for Genomic Bereavement Care
Completed NCT03847909 - A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2 Phase 2
Completed NCT04584528 - Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease N/A
Not yet recruiting NCT06048523 - Prospective Cohort Study of Neurogenetic Diseases N/A
Completed NCT02225522 - Genomic Sequencing in Acutely Ill Neonates N/A
Enrolling by invitation NCT06089954 - Penn Medicine Biobank Return of Results Program N/A
Completed NCT03713333 - Implementing Digital Health in a Learning Health System N/A
Completed NCT03309605 - Phase 1 Study of ELX-02 in Healthy Adult Subjects Phase 1
Recruiting NCT05499091 - Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN N/A
Completed NCT04556487 - Turkish Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS)
Completed NCT04556500 - Turkish Version of the Affordance in the Home Environment for Motor Development-Toddler (AHEMD-T)
Recruiting NCT02551081 - Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units